Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119


Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer.

Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, Kang MI, Kobayashi A, Yokoyama S, Yamamoto M.

Mol Cell. 2006 Mar 3;21(5):689-700.


Crystal structure of the Kelch domain of human Keap1.

Li X, Zhang D, Hannink M, Beamer LJ.

J Biol Chem. 2004 Dec 24;279(52):54750-8. Epub 2004 Oct 8.


Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model.

Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, Yamamoto M.

Mol Cell Biol. 2006 Apr;26(8):2887-900.


Structural insights into the similar modes of Nrf2 transcription factor recognition by the cytoplasmic repressor Keap1.

Padmanabhan B, Tong KI, Kobayashi A, Yamamoto M, Yokoyama S.

J Synchrotron Radiat. 2008 May;15(Pt 3):273-6. doi: 10.1107/S090904950705114X. Epub 2008 Apr 18.


Keap1 is a forked-stem dimer structure with two large spheres enclosing the intervening, double glycine repeat, and C-terminal domains.

Ogura T, Tong KI, Mio K, Maruyama Y, Kurokawa H, Sato C, Yamamoto M.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2842-7. doi: 10.1073/pnas.0914036107. Epub 2010 Jan 27.


Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response.

Tong KI, Padmanabhan B, Kobayashi A, Shang C, Hirotsu Y, Yokoyama S, Yamamoto M.

Mol Cell Biol. 2007 Nov;27(21):7511-21. Epub 2007 Sep 4.


Structural analysis of the complex of Keap1 with a prothymosin alpha peptide.

Padmanabhan B, Nakamura Y, Yokoyama S.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008 Apr 1;64(Pt 4):233-8. doi: 10.1107/S1744309108004995. Epub 2008 Mar 21.


Molecular effects of cancer-associated somatic mutations on the structural and target recognition properties of Keap1.

Khan H, Killoran RC, Brickenden A, Fan J, Yang D, Choy WY.

Biochem J. 2015 Apr 1;467(1):141-51. doi: 10.1042/BJ20140761.


Characterizations of Three Major Cysteine Sensors of Keap1 in Stress Response.

Saito R, Suzuki T, Hiramoto K, Asami S, Naganuma E, Suda H, Iso T, Yamamoto H, Morita M, Baird L, Furusawa Y, Negishi T, Ichinose M, Yamamoto M.

Mol Cell Biol. 2015 Nov 2;36(2):271-84. doi: 10.1128/MCB.00868-15.


Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes.

Kang MI, Kobayashi A, Wakabayashi N, Kim SG, Yamamoto M.

Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2046-51. Epub 2004 Feb 5.


p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription.

Jain A, Lamark T, Sjøttem E, Larsen KB, Awuh JA, Øvervatn A, McMahon M, Hayes JD, Johansen T.

J Biol Chem. 2010 Jul 16;285(29):22576-91. doi: 10.1074/jbc.M110.118976. Epub 2010 May 7.


Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination.

Hast BE, Goldfarb D, Mulvaney KM, Hast MA, Siesser PF, Yan F, Hayes DN, Major MB.

Cancer Res. 2013 Apr 1;73(7):2199-210. doi: 10.1158/0008-5472.CAN-12-4400. Epub 2013 Feb 4.


Kinetic, thermodynamic, and structural characterizations of the association between Nrf2-DLGex degron and Keap1.

Fukutomi T, Takagi K, Mizushima T, Ohuchi N, Yamamoto M.

Mol Cell Biol. 2014 Mar;34(5):832-46. doi: 10.1128/MCB.01191-13. Epub 2013 Dec 23.


Cysteine-based regulation of the CUL3 adaptor protein Keap1.

Sekhar KR, Rachakonda G, Freeman ML.

Toxicol Appl Pharmacol. 2010 Apr 1;244(1):21-6. doi: 10.1016/j.taap.2009.06.016. Epub 2009 Jun 26. Review.


Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling.

Lo SC, Li X, Henzl MT, Beamer LJ, Hannink M.

EMBO J. 2006 Aug 9;25(15):3605-17. Epub 2006 Aug 3.


Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.

Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E, Brock MV, Biswal S.

PLoS Med. 2006 Oct;3(10):e420.

Supplemental Content

Support Center